Safety, Tolerability, Pharmacokinetics, and Immunogenicity of a Monoclonal Antibody (SCTA01) Targeting SARS-CoV-2 in Healthy Adults: a Randomized, Double-Blind, Placebo-Controlled, Phase I Study

SCTA01 is a novel monoclonal antibody with promising prophylactic and therapeutic potential for COVID-19. This study aimed to evaluate the safety, tolerability, pharmacokinetics (PK) and immunogenicity of SCTA01 in healthy adults. This was a randomized, double-blind, placebo-controlled, dose escalat...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Yinjuan, Qi, Lu, Bai, Haihong, Sun, Chunyun, Xu, Shuping, Wang, Yu, Han, Chunyu, Li, Yan, Liu, Long, Cheng, Xiaoqiang, Liu, Ju, Lei, Chunpu, Tong, Yuanxu, Sun, Mingli, Yan, Lixin, Chen, Weiqiu, Liu, Xisheng, Liu, Qing, Xie, Liangzhi, Wang, Xinghe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2021
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522782/
https://www.ncbi.nlm.nih.gov/pubmed/34491805
http://dx.doi.org/10.1128/AAC.01063-21

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8522782/
https://www.ncbi.nlm.nih.gov/pubmed/34491805
http://dx.doi.org/10.1128/AAC.01063-21

Ejemplares similares